Abstract: A package for a medical device includes a folder having bottom and top panels, the bottom panel including a leading edge, a trailing edge, and at least one medical device securing element. The top panel has a leading edge, and a trailing edge joined with the trailing edge of the bottom panel. The folder has an unfolded configuration in which the leading edges of the top and bottom panels face in opposite directions, and a folded configuration in which the top panel is folded over the bottom panel so that the leading edges of the top and bottom panels face in the same direction and are aligned with one another. The folder is insertable into a sealable pouch having a seal with a first leg whereby the leading edges of the folder are abutted against the first leg of the seal of the pouch.

Abstract: A package for a medical device includes a folder having bottom and top panels, the bottom panel including a leading edge, a trailing edge, and at least one medical device securing element. The top panel has a leading edge, and a trailing edge joined with the trailing edge of the bottom panel. The folder has an unfolded configuration in which the leading edges of the top and bottom panels face in opposite directions, and a folded configuration in which the top panel is folded over the bottom panel so that the leading edges of the top and bottom panels face in the same direction and are aligned with one another. The folder is insertable into a sealable pouch having a seal with a first leg whereby the leading edges of the folder are abutted against the first leg of the seal of the pouch.

Abstract: This invention relates to a transdermal patch in the form of a layer complex, comprising a backing layer, a drug-reservoir layer comprising pharmacologically active ingredients and pharmaceutically acceptable adjuvants, and a release liner covering the drug-reservoir layer, characterized in that the drug-reservoir layer comprises isosorbide dinitrate and Bisoprolol at a ratio of 1:3 to 3:1 by weight, as the pharmacologically active ingredients. Animal tests show that said patch can reduce the elevation of T wave of cardiogram, the increase of the level of myocardial enzyme in blood serum, and the extension of the range of myocardial infarction caused by ligating the coronary artery in animals. Results show that said patch exhibits a considerable synergistic effect in the treatment of cardiovascular diseases and has good preventive and therapeutic effects on several adverse events on heart.

Abstract: This invention relates to a transdermal patch in the form of a layer complex, comprising a backing layer, a drug-reservoir layer comprising pharmacologically active ingredients and pharmaceutically acceptable adjuvants, and a release liner covering the drug-reservoir layer, characterized in that the drug-reservoir layer comprises isosorbide dinitrate and Bisoprolol at a ratio of 1:3 to 3:1 by weight, as the pharmacologically active ingredients. Animal tests show that said patch can reduce the elevation of T wave of cardiogram, the increase of the level of myocardial enzyme in blood serum, and the extension of the range of myocardial infarction caused by ligating the coronary artery in animals. Results show that said patch exhibits a considerable synergistic effect in the treatment of cardiovascular diseases and has good preventive and therapeutic effects on several adverse events on heart.